Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2024-04-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
独立董事2023年度述职报告（刘建伟）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Work Report" for the company. It details the independent director's attendance at meetings, opinions on various board matters, committee work, investigations, and efforts to protect investor rights during the year 2023. It is a narrative report on the director's duties and activities rather than a financial report or announcement. The content aligns with a management or board-related report focusing on governance and director responsibilities. It is not an annual report (10-K), audit report, earnings release, or any other financial filing. It is best classified under Board/Management Information (MANG) as it relates to board member activities and governance reporting.
2024-04-22 Chinese
关于董事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of a new board of directors for the company 拓新药业集团股份有限公司. It details the nomination and qualifications of candidates for the fifth board, including both independent and non-independent directors, and references compliance with relevant laws and regulations. There is no financial data or report content, but rather a formal disclosure about board changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length is 3560 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2024-04-22 Chinese
拓新药业集团股份有限公司2023年度非经营性资金占用及其他关联资金往来的专项说明
Regulatory Filings Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding non-operating fund occupation and other related party fund transactions for the year 2023 of 拓新药业集团股份有限公司. It references the 2023 audited financial statements and an unqualified audit report issued on April 22, 2024. The document includes a summary table of related party fund transactions and states it was prepared according to regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is only 2413 characters long, which is quite short and does not contain full financial statements or detailed financial analysis. It is a supplementary disclosure related to the annual report but not the annual report itself. It is not a certification letter, management report, or earnings release. Given the nature of the document as a special explanatory note on related party transactions and fund occupation, and its short length, it fits best as a Regulatory Filing (RNS) rather than a full Annual Report (10-K) or Audit Report (AR).
2024-04-22 Chinese
中天国富证券有限公司关于拓新药业集团股份有限公司使用部分超募资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of excess raised funds by a listed company (拓新药业集团股份有限公司). It references regulatory rules related to the use of raised funds, board and supervisory committee approvals, and the compliance with stock exchange listing rules. The document includes specifics about the amount of funds used, approvals by various company bodies, and the sponsoring institution's opinion. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript or presentation. It is a regulatory compliance and verification report related to capital use, specifically about the use of excess raised funds to supplement working capital. This fits best under the category of Capital/Financing Update (CAP), as it concerns updates on the company's fundraising and capital usage activities. The document length is about 3000 characters, which is substantive and not a mere announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2024-04-22 Chinese
上市公司独立董事提名人声明与承诺-刘建伟
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment by a nominator regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the candidate's qualifications, compliance with laws and regulations, and independence criteria. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management information, specifically about the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is sufficient and the content is substantive, not a mere announcement or certification.
2024-04-22 Chinese
第四届监事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 21st meeting of the 4th Supervisory Board of the company, including approvals of the 2023 annual report, financial statements, profit distribution plan, remuneration plan, internal control report, and other governance matters. It repeatedly states that these resolutions will be submitted to the 2023 annual shareholders' meeting for approval. The document is not the annual report itself but a formal announcement of the supervisory board's meeting decisions and approvals related to governance and financial reports. It also includes nominations for the new supervisory board and appointment of the audit firm. The document is a formal meeting resolution announcement rather than a full financial report or earnings release. Therefore, it fits best under Board/Management Information (MANG) as it relates to supervisory board meeting resolutions and governance decisions.
2024-04-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.